MonoTotal ELISA has been CE marked in accordance with the European IVD Directive | IDL Biotech
IDL Biotech

CLOSE MENU

Articles

Lung cancer

June 2013

MonoTotal ELISA has been CE marked in accordance with the European IVD Directive

IDL Biotech tumor marker MonoTotal® ELISA has been registered by the Swedish Medical Product Agency for the use in the EU.

MonoTotal® is used for diagnosis, prognosis and therapy monitoring of lung cancer.

MonoTotal® has previously only been available as a radioactive immunoassay (MonoTotal® IRMA). The use of radioactive immunoassays is limited to very few countries. IDL Biotech has now developed an ELISA version of MonoTotal® with equal performance to the radioactive immunoassay; ELISA technology is a global standard method, thus providing many more countries an opportunity to use the product.

 

Lung cancer is one of the most common cancer forms with a high mortality rate. Early diagnose and good prognosis contributes to improved survival rates. Control after surgery and follow up after cancer treatment are also important factors in the management of patients. MonoTotal® is therefore an important complement to other clinical methods.

IDL has hired a new production manager

IDL is proud to announce that Jeanpierre Salas Montes will take over as production manager at IDL Biotech. Ola Eklund has decided to retire after more than 20 years at IDL.

Charlotte Berg leaves the position as CEO of IDL Biotech AB (publ)

IDL Biotech's CEO, Charlotte Berg, has informed the Board that, after more than ten years at the company, she wishes to resign as CEO to start another assignment in a non-competing company.

IDL Biotech

Skip this intro